Key result
Vaccine-linked chemotherapy reduces cardiac fibrosis ~25% vs untreated controls in T. cruzi-infected mice.
Why the study?
Benznidazole induces toxicity and fails to halt chronic chagasic cardiomyopathy progression in chronic patients, warranting evaluation of low-dose benznidazole combined with a therapeutic recombinant protein vaccine to prevent cardiac disease progression.
Does a therapeutic vaccine combined with low-dose benznidazole prevent cardiac fibrosis in BALB/c mice chronically infected with Trypanosoma cruzi?
Does a therapeutic vaccine combined with low-dose benznidazole prevent cardiac fibrosis in BALB/c mice chronically infected with Trypanosoma cruzi?
Bivalent immunotherapy combined with low-dose benznidazole during early chronic Trypanosoma cruzi infection protects against cardiac fibrosis progression and induces strong CD8+ T cell immunity in a mouse model.
Answers are grounded in this paper and cite their sources.
Supports testing vaccine-linked chemotherapy to limit fibrosis in chronic Chagas; leaves open human translation from this mouse model.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Dzul-Huchim et al. (2022) studied Trypanosoma cruzi chronic infection (Chagas disease) (n=74). Vaccine-linked chemotherapy (low dose benznidazole + bivalent recombinant protein vaccine) vs. Infected untreated control (vehicle solution) was evaluated on Cardiac fibrosis percentage area at day 200 post-infection (p=0.013). Vaccine-linked chemotherapy with low-dose benznidazole and a bivalent recombinant protein vaccine reduced cardiac fibrosis compared to untreated controls in T. cruzi-infected mice.
Synapse has enriched 10 related papers. Consider them for comparative context: